No Data
Trending Stocks Today | The Real Good Food Shoots up 64.89% Post-Market
SEC Charges Cassava Sciences, Two Former Executives For Misleading Claims About Alzheimer's Clinical Trial; Company To Pay Civil Penalty Of $40M
Express News | U.S. SEC Says It Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer’s Clinical Trial
Cassava Sciences (SAVA.US) received DSMB approval for the late-stage trial progress of Alzheimer's disease therapy.
Cassava Sciences announced that it has completed the third mid-stage safety review of simufilam in an important late-stage clinical trial for the treatment of Alzheimer's patients currently being conducted by the company.
Cassava Sciences' On-going Late Stage Trials for Alzheimer's Treatment Gets DSMB Nod
Express News | Cassava Sciences Inc - Dsmb Recommends Continuation of Phase 3 Trials Without Modification
blackkeymatch : Demo testing...
blackkeymatch : Today very security approve.. warp up